TY - JOUR AU - Siegel, R. L. AU - Miller, K. D. AU - Jemal, A. PY - 2018 DA - 2018// TI - Cancer statistics, 2018 JO - CA Cancer J Clin VL - 68 UR - https://doi.org/10.3322/caac.21442 DO - 10.3322/caac.21442 ID - Siegel2018 ER - TY - JOUR AU - Fan, L. AU - Strasser-Weippl, K. AU - Li, J. J. AU - St Louis, J. AU - Finkelstein, D. M. AU - Yu, K. D. PY - 2014 DA - 2014// TI - Breast cancer in China JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/s1470-2045(13)70567-9 DO - 10.1016/s1470-2045(13)70567-9 ID - Fan2014 ER - TY - JOUR AU - Momenimovahed, Z. AU - Salehiniya, H. PY - 2019 DA - 2019// TI - Epidemiological characteristics of and risk factors for breast cancer in the world JO - Breast Cancer (Dove Medical Press) VL - 11 UR - https://doi.org/10.2147/bctt.S176070 DO - 10.2147/bctt.S176070 ID - Momenimovahed2019 ER - TY - JOUR AU - Tabar, L. AU - Fagerberg, C. J. AU - Gad, A. AU - Baldetorp, L. AU - Holmberg, L. H. AU - Grontoft, O. PY - 1985 DA - 1985// TI - Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish National Board of Health and Welfare JO - Lancet (London, England) VL - 1 UR - https://doi.org/10.1016/S0140-6736(85)92204-4 DO - 10.1016/S0140-6736(85)92204-4 ID - Tabar1985 ER - TY - JOUR AU - Zou, L. AU - Yu, S. AU - Meng, T. AU - Zhang, Z. AU - Liang, X. AU - Xie, Y. PY - 2019 DA - 2019// TI - A technical review of convolutional neural network-based mammographic breast Cancer diagnosis JO - Comput Math Methods Med VL - 2019 UR - https://doi.org/10.1155/2019/6509357 DO - 10.1155/2019/6509357 ID - Zou2019 ER - TY - JOUR AU - Moelans, C. B. AU - Weger, R. A. AU - Wall, E. AU - Diest, P. J. PY - 2011 DA - 2011// TI - Current technologies for HER2 testing in breast cancer JO - Crit Rev Oncol Hematol VL - 80 UR - https://doi.org/10.1016/j.critrevonc.2010.12.005 DO - 10.1016/j.critrevonc.2010.12.005 ID - Moelans2011 ER - TY - JOUR AU - Yeh, I. T. PY - 2002 DA - 2002// TI - Measuring HER-2 in breast cancer. Immunohistochemistry, FISH, or ELISA? JO - Am J Clin Pathol VL - 117 ID - Yeh2002 ER - TY - JOUR AU - Slamon, D. J. AU - Clark, G. M. AU - Wong, S. G. AU - Levin, W. J. AU - Ullrich, A. AU - McGuire, W. L. PY - 1987 DA - 1987// TI - Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene JO - Science VL - 235 UR - https://doi.org/10.1126/science.3798106 DO - 10.1126/science.3798106 ID - Slamon1987 ER - TY - JOUR AU - Goldhirsch, A. AU - Ingle, J. N. AU - Gelber, R. D. AU - Coates, A. S. AU - Thurlimann, B. AU - Senn, H. J. PY - 2009 DA - 2009// TI - Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009 JO - Ann Oncol VL - 20 UR - https://doi.org/10.1093/annonc/mdp322 DO - 10.1093/annonc/mdp322 ID - Goldhirsch2009 ER - TY - JOUR AU - Bilous, M. AU - Dowsett, M. AU - Hanna, W. AU - Isola, J. AU - Lebeau, A. AU - Moreno, A. PY - 2003 DA - 2003// TI - Current perspectives on HER2 testing: a review of national testing guidelines JO - Mod Pathol VL - 16 UR - https://doi.org/10.1097/01.Mp.0000052102.90815.82 DO - 10.1097/01.Mp.0000052102.90815.82 ID - Bilous2003 ER - TY - JOUR AU - Yaziji, H. AU - Goldstein, L. C. AU - Barry, T. S. AU - Werling, R. AU - Hwang, H. AU - Ellis, G. K. PY - 2004 DA - 2004// TI - HER-2 testing in breast cancer using parallel tissue-based methods JO - Jama VL - 291 UR - https://doi.org/10.1001/jama.291.16.1972 DO - 10.1001/jama.291.16.1972 ID - Yaziji2004 ER - TY - JOUR AU - Baselga, J. J. C. C. R. PY - 2001 DA - 2001// TI - Is circulating HER-2 more than just a tumor marker? JO - Clin Cancer Res VL - 7 ID - Baselga2001 ER - TY - JOUR AU - Yamauchi, H. AU - Stearns, V. AU - Hayes, D. F. PY - 2001 DA - 2001// TI - When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/jco.2001.19.8.2334 DO - 10.1200/jco.2001.19.8.2334 ID - Yamauchi2001 ER - TY - JOUR AU - Carney, W. P. AU - Neumann, R. AU - Lipton, A. AU - Leitzel, K. AU - Ali, S. AU - Price, C. P. PY - 2003 DA - 2003// TI - Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer JO - Clin Chem VL - 49 UR - https://doi.org/10.1373/49.10.1579 DO - 10.1373/49.10.1579 ID - Carney2003 ER - TY - JOUR AU - Carney, W. P. AU - Neumann, R. AU - Lipton, A. AU - Leitzel, K. AU - Ali, S. AU - Price, C. P. PY - 2004 DA - 2004// TI - Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer JO - Clin Breast Cancer VL - 5 UR - https://doi.org/10.3816/CBC.2004.n.014 DO - 10.3816/CBC.2004.n.014 ID - Carney2004 ER - TY - JOUR AU - Jensen, B. V. AU - Johansen, J. S. AU - Price, P. A. PY - 2003 DA - 2003// TI - High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer JO - Clin Cancer Res VL - 9 ID - Jensen2003 ER - TY - JOUR AU - Kong, S. Y. AU - Nam, B. H. AU - Lee, K. S. AU - Kwon, Y. AU - Lee, E. S. AU - Seong, M. W. PY - 2006 DA - 2006// TI - Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer JO - Clin Chem VL - 52 UR - https://doi.org/10.1373/clinchem.2006.067512 DO - 10.1373/clinchem.2006.067512 ID - Kong2006 ER - TY - JOUR AU - Ali, S. M. AU - Carney, W. P. AU - Esteva, F. J. AU - Fornier, M. AU - Harris, L. AU - Kostler, W. J. PY - 2008 DA - 2008// TI - Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer JO - Cancer VL - 113 UR - https://doi.org/10.1002/cncr.23689 DO - 10.1002/cncr.23689 ID - Ali2008 ER - TY - JOUR AU - Ryu, D. W. AU - Lee, C. H. PY - 2012 DA - 2012// TI - Impact of serum HER2 levels on survival and its correlation with Clinicopathological parameters in women with breast Cancer JO - J Breast Cancer VL - 15 UR - https://doi.org/10.4048/jbc.2012.15.1.71 DO - 10.4048/jbc.2012.15.1.71 ID - Ryu2012 ER - TY - JOUR AU - Lam, L. AU - McAndrew, N. AU - Yee, M. AU - Fu, T. AU - Tchou, J. C. AU - Zhang, H. PY - 2012 DA - 2012// TI - Challenges in the clinical utility of the serum test for HER2 ECD JO - Biochim Biophys Acta VL - 1826 UR - https://doi.org/10.1016/j.bbcan.2012.03.012 DO - 10.1016/j.bbcan.2012.03.012 ID - Lam2012 ER - TY - JOUR AU - Harris, L. AU - Fritsche, H. AU - Mennel, R. AU - Norton, L. AU - Ravdin, P. AU - Taube, S. PY - 2007 DA - 2007// TI - American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/jco.2007.14.2364 DO - 10.1200/jco.2007.14.2364 ID - Harris2007 ER - TY - JOUR AU - Olsen, D. A. AU - Østergaard, B. AU - Bokmand, S. AU - Wamberg, P. A. AU - Jakobsen, E. H. AU - Brandslund, I. PY - 2007 DA - 2007// TI - HER-2 protein concentrations in breast cancer cells increase before immunohistochemical and fluorescence in situ hybridization analysis turn positive JO - Clin Chem Lab Med VL - 45 UR - https://doi.org/10.1515/CCLM.2007.034 DO - 10.1515/CCLM.2007.034 ID - Olsen2007 ER - TY - JOUR AU - Ludovini, V. AU - Gori, S. AU - Colozza, M. AU - Pistola, L. AU - Rulli, E. AU - Floriani, I. PY - 2008 DA - 2008// TI - Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdm585 DO - 10.1093/annonc/mdm585 ID - Ludovini2008 ER - TY - JOUR AU - Papadopoulou, E. AU - Tripsianis, G. AU - Anagnostopoulos, K. AU - Tentes, I. AU - Kakolyris, S. AU - Galazios, G. PY - 2008 DA - 2008// TI - The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome JO - Neoplasma VL - 55 ID - Papadopoulou2008 ER - TY - JOUR AU - Savino, M. AU - Parrella, P. AU - Copetti, M. AU - Barbano, R. AU - Murgo, R. AU - Fazio, V. M. PY - 2009 DA - 2009// TI - Comparison between real-time quantitative PCR detection of HER2 mRNA copy number in peripheral blood and ELISA of serum HER2 protein for determining HER2 status in breast cancer patients JO - Cell Oncol VL - 31 UR - https://doi.org/10.3233/clo-2009-0468 DO - 10.3233/clo-2009-0468 ID - Savino2009 ER - TY - JOUR AU - Finn, R. S. AU - Gagnon, R. AU - Leo, A. AU - Press, M. F. AU - Arbushites, M. AU - Koehler, M. PY - 2009 DA - 2009// TI - Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/jco.2008.21.1763 DO - 10.1200/jco.2008.21.1763 ID - Finn2009 ER - TY - JOUR AU - Farzadnia, M. AU - Meibodi, N. T. AU - Shandiz, F. H. AU - Mahmoudi, M. AU - Bahar, M. M. AU - Memar, B. PY - 2010 DA - 2010// TI - Evaluation of HER2/neu oncoprotein in serum and tissue samples of women with breast cancer: correlation with clinicopathological parameters JO - Breast VL - 19 UR - https://doi.org/10.1016/j.breast.2010.05.012 DO - 10.1016/j.breast.2010.05.012 ID - Farzadnia2010 ER - TY - JOUR AU - Lauterlein, J. J. AU - Petersen, E. R. AU - Olsen, D. A. AU - Ostergaard, B. AU - Brandslund, I. PY - 2011 DA - 2011// TI - Quantification of HER2 autoantibodies in the amplification phenomenon of HER2 in breast cancer JO - Clin Chem Lab Med VL - 49 UR - https://doi.org/10.1515/cclm.2011.135 DO - 10.1515/cclm.2011.135 ID - Lauterlein2011 ER - TY - JOUR AU - Sørensen, P. D. AU - Jakobsen, E. H. AU - Madsen, J. S. AU - Petersen, E. B. AU - Andersen, R. F. AU - Østergaard, B. PY - 2013 DA - 2013// TI - Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients JO - J Cancer Res Clin Oncol VL - 139 UR - https://doi.org/10.1007/s00432-013-1411-7 DO - 10.1007/s00432-013-1411-7 ID - Sørensen2013 ER - TY - JOUR AU - Pedersen, A. C. AU - Sørensen, P. D. AU - Jacobsen, E. H. AU - Madsen, J. S. AU - Brandslund, I. PY - 2013 DA - 2013// TI - Sensitivity of CA 15-3, CEA and serum HER2 in the early detection of recurrence of breast cancer JO - Clin Chem Lab Med VL - 51 UR - https://doi.org/10.1515/cclm-2012-0488 DO - 10.1515/cclm-2012-0488 ID - Pedersen2013 ER - TY - STD TI - Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P. Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer. Clin Chim Acta. 2014;430:86–91. https://doi.org/10.1016/j.cca.2013.12.036. Epub 2014 Jan 9. PMID: 24412321. ID - ref31 ER - TY - JOUR AU - Gioia, D. AU - Dresse, M. AU - Mayr, D. AU - Nagel, D. AU - Heinemann, V. AU - Stieber, P. PY - 2015 DA - 2015// TI - Serum HER2 in combination with CA 15–3 as a parameter for prognosis in patients with early breast cancer JO - Clin Chim Acta VL - 440 UR - https://doi.org/10.1016/j.cca.2014.11.001 DO - 10.1016/j.cca.2014.11.001 ID - Gioia2015 ER - TY - JOUR AU - Banys-Paluchowski, M. AU - Witzel, I. AU - Riethdorf, S. AU - Rack, B. AU - Janni, W. AU - Fasching, P. A. PY - 2017 DA - 2017// TI - Clinical relevance of serum HER2 and circulating tumor cell detection in metastatic breast cancer patients JO - Anticancer Res VL - 37 UR - https://doi.org/10.21873/anticanres.11669 DO - 10.21873/anticanres.11669 ID - Banys-Paluchowski2017 ER - TY - STD TI - Broughton MN, Westgaard A, Paus E, Øijordsbakken M, Henanger KJ, Naume B, et al. Specific antibodies and sensitive immunoassays for the human epidermal growth factor receptors (HER2, HER3, and HER4). Tumor Biol. 2017;39(6). https://doi.org/10.1177/1010428317707436. ID - ref34 ER - TY - JOUR AU - Trevethan, R. PY - 2017 DA - 2017// TI - Sensitivity, specificity, and predictive values: foundations, Pliabilities, and pitfalls in research and practice JO - Front Public Health VL - 5 UR - https://doi.org/10.3389/fpubh.2017.00307 DO - 10.3389/fpubh.2017.00307 ID - Trevethan2017 ER - TY - STD TI - White S, Schultz T, Enuameh YAK. Synthesizing evidence of diagnostic accuracy. Philadelphia: Lippincott Williams & Wilkins; 2011. ID - ref36 ER - TY - JOUR AU - Albarello, L. AU - Pecciarini, L. AU - Doglioni, C. PY - 2011 DA - 2011// TI - HER2 testing in gastric cancer JO - Adv Anat Pathol VL - 18 UR - https://doi.org/10.1097/PAP.0b013e3182026d72 DO - 10.1097/PAP.0b013e3182026d72 ID - Albarello2011 ER - TY - JOUR AU - Jacobs, T. W. AU - Gown, A. M. AU - Yaziji, H. AU - Barnes, M. J. AU - Schnitt, S. J. PY - 1999 DA - 1999// TI - Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer JO - J Clin Oncol VL - 17 UR - https://doi.org/10.1200/jco.1999.17.7.1974 DO - 10.1200/jco.1999.17.7.1974 ID - Jacobs1999 ER - TY - JOUR AU - Colomer, R. AU - Montero, S. AU - Lluch, A. AU - Ojeda, B. AU - Barnadas, A. AU - Casado, A. PY - 2000 DA - 2000// TI - Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer JO - Clin Cancer Res VL - 6 ID - Colomer2000 ER - TY - JOUR AU - Esteva, F. J. AU - Cheli, C. D. AU - Fritsche, H. AU - Fornier, M. AU - Slamon, D. AU - Thiel, R. P. PY - 2005 DA - 2005// TI - Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies JO - Breast Cancer Res VL - 7 UR - https://doi.org/10.1186/bcr1020 DO - 10.1186/bcr1020 ID - Esteva2005 ER - TY - JOUR AU - Bossuyt, P. M. PY - 2008 DA - 2008// TI - Interpreting diagnostic test accuracy studies JO - Semin Hematol VL - 45 UR - https://doi.org/10.1053/j.seminhematol.2008.04.001 DO - 10.1053/j.seminhematol.2008.04.001 ID - Bossuyt2008 ER - TY - JOUR AU - Knottnerus, J. A. AU - Weel, C. AU - Muris, J. W. PY - 2002 DA - 2002// TI - Evaluation of diagnostic procedures JO - BMJ VL - 324 UR - https://doi.org/10.1136/bmj.324.7335.477 DO - 10.1136/bmj.324.7335.477 ID - Knottnerus2002 ER - TY - JOUR AU - Šimundić, A. M. PY - 2009 DA - 2009// TI - Measures of diagnostic accuracy: basic definitions JO - Ejifcc VL - 19 ID - Šimundić2009 ER - TY - STD TI - Luckmann R. Evidence-Based Medicine: How to Practice and Teach EBM, 2nd Edition: In: By David L. Sackett, Sharon E. Straus, W. Scott Richardson, William Rosenberg, and R. Brian Haynes, Churchill Livingstone, 2000. Vol. 16. Issue (3). 2001. p. 155–156. https://doi.org/10.1177/088506660101600307. ID - ref44 ER - TY - JOUR AU - Deeks, J. J. AU - Altman, D. G. PY - 2004 DA - 2004// TI - Diagnostic tests 4: likelihood ratios JO - BMJ VL - 329 UR - https://doi.org/10.1136/bmj.329.7458.168 DO - 10.1136/bmj.329.7458.168 ID - Deeks2004 ER - TY - STD TI - Guyatt G, Rennie D, Meade M, Cook D. Users’ guides to the medical literature: a manual for evidence-based clinical practice. Chicago: American Medical Association; 2002. ID - ref46 ER - TY - JOUR AU - Leeflang, M. M. PY - 2014 DA - 2014// TI - Systematic reviews and meta-analyses of diagnostic test accuracy JO - Clin Microbiol Infect VL - 20 UR - https://doi.org/10.1111/1469-0691.12474 DO - 10.1111/1469-0691.12474 ID - Leeflang2014 ER - TY - JOUR AU - Zhang, K. AU - Cui, J. AU - Xi, H. AU - Bian, S. AU - Ma, L. AU - Shen, W. PY - 2015 DA - 2015// TI - Serum HER2 is a potential surrogate for tissue HER2 status in gastric Cancer: a systematic review and meta-analysis JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0136322 DO - 10.1371/journal.pone.0136322 ID - Zhang2015 ER - TY - JOUR AU - Shamshirian, A. AU - Heydari, K. AU - Aref, A. R. AU - Alizadeh-Navaei, R. AU - Shamshirian, D. AU - Hamzehgardeshi, Z. AU - Moosazadeh, M. PY - 2019 DA - 2019// TI - 20P - Diagnostic value of serum HER-2 level in compression with tissue HER-2 in breast cancer: A systematic review and meta-analysis JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdz416.019 DO - 10.1093/annonc/mdz416.019 ID - Shamshirian2019 ER -